## Francesca Fanelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6042313/publications.pdf Version: 2024-02-01



EDANCESCA FANELLI

#	Article	IF	CITATIONS
1	The Lutropin/Choriogonadotropin Receptor, A 2002 Perspective. Endocrine Reviews, 2002, 23, 141-174.	8.9	671
2	Adenosine A2A-Dopamine D2 Receptor-Receptor Heteromerization. Journal of Biological Chemistry, 2003, 278, 46741-46749.	1.6	401
3	Constitutively active mutants of the alpha 1B-adrenergic receptor: role of highly conserved polar amino acids in receptor activation EMBO Journal, 1996, 15, 3566-3578.	3.5	338
4	Target Flexibility: An Emerging Consideration in Drug Discovery and Design. Journal of Medicinal Chemistry, 2008, 51, 6237-6255.	2.9	280
5	Wordom: A userâ€friendly program for the analysis of molecular structures, trajectories, and free energy surfaces. Journal of Computational Chemistry, 2011, 32, 1183-1194.	1.5	232
6	The activation process of the Â1B-adrenergic receptor: Potential role of protonation and hydrophobicity of a highly conserved aspartate. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 808-813.	3.3	207
7	The Lutropin/Choriogonadotropin Receptor, A 2002 Perspective. , 2002, 23, 141-174.		167
8	Computational Modeling Approaches to Structureâ^Function Analysis of G Protein-Coupled Receptors. Chemical Reviews, 2005, 105, 3297-3351.	23.0	158
9	Adenosine A2A-dopamine D2 receptor–receptor heteromers. Targets for neuro-psychiatric disorders. Parkinsonism and Related Disorders, 2004, 10, 265-271.	1.1	132
10	Adenosine A <sub>2A</sub> Receptor-Antagonist/Dopamine D <sub>2</sub> Receptor-Agonist Bivalent Ligands as Pharmacological Tools to Detect A <sub>2A</sub> -D <sub>2</sub> Receptor Heteromers. Journal of Medicinal Chemistry, 2009, 52, 5590-5602.	2.9	129
11	Mutagenesis and Modelling of the α1b-Adrenergic Receptor Highlight the Role of the Helix 3/Helix 6 Interface in Receptor Activation. Molecular Pharmacology, 2002, 61, 1025-1032.	1.0	114
12	The KDEL receptor couples to Gα <sub>q/11</sub> to activate Src kinases and regulate transport through the Golgi. EMBO Journal, 2012, 31, 2869-2881.	3.5	105
13	Single Molecule Analysis of Functionally Asymmetric G Protein-coupled Receptor (GPCR) Oligomers Reveals Diverse Spatial and Structural Assemblies. Journal of Biological Chemistry, 2015, 290, 3875-3892.	1.6	105
14	Constitutively active mutants of the alpha 1B-adrenergic receptor: role of highly conserved polar amino acids in receptor activation. EMBO Journal, 1996, 15, 3566-78.	3.5	95
15	The intellectual disability protein RAB39B selectively regulates GluA2 trafficking to determine synaptic AMPAR composition. Nature Communications, 2015, 6, 6504.	5.8	93
16	Mutational analysis of the highly conserved arginine within the Glu/Asp-Arg-Tyr motif of the alpha(1b)-adrenergic receptor: effects on receptor isomerization and activation. Molecular Pharmacology, 2000, 57, 219-31.	1.0	93
17	Activation Mechanism of Human Oxytocin Receptor: A Combined Study of Experimental and Computer-Simulated Mutagenesis. Molecular Pharmacology, 1999, 56, 214-225.	1.0	88
18	Hydrophobicity of Residue351of the G Protein Gi1α Determines the Extent of Activation by the α2A-Adrenoceptorâ€. Biochemistry, 1998, 37, 11555-11562.	1.2	87

#	Article	IF	CITATIONS
19	Inverse Agonism and Neutral Antagonism at α <sub>1a</sub> - and α <sub>1b</sub> -Adrenergic Receptor Subtypes. Molecular Pharmacology, 1999, 56, 858-866.	1.0	86
20	Mutational and Computational Analysis of the ${\rm \hat{l}}\pm 1 \rm b$ -Adrenergic Receptor. Journal of Biological Chemistry, 2001, 276, 46485-46494.	1.6	73
21	Update 1 of: Computational Modeling Approaches to Structure–Function Analysis of G Protein-Coupled Receptors. Chemical Reviews, 2011, 111, PR438-PR535.	23.0	71
22	Amino acids of theα1B-adrenergic receptor involved in agonist binding: differences in docking catecholamines to receptor subtypes. FEBS Letters, 1996, 399, 9-13.	1.3	70
23	A Model for Constitutive Lutropin Receptor Activation Based on Molecular Simulation and Engineered Mutations in Transmembrane Helices 6 and 7. Journal of Biological Chemistry, 2002, 277, 32202-32213.	1.6	67
24	Auto-regulation of Secretory Flux by Sensing and Responding to the Folded Cargo Protein Load in the Endoplasmic Reticulum. Cell, 2019, 176, 1461-1476.e23.	13.5	65
25	A functional transmembrane complex: The luteinizing hormone receptor with bound ligand and G protein. Molecular and Cellular Endocrinology, 2007, 260-262, 126-136.	1.6	63
26	Theoretical investigation of substrate specificity for cytochromes P450 IA2, P450 IID6 and P450 IIIA4. Journal of Computer-Aided Molecular Design, 2000, 14, 93-116.	1.3	59
27	Dimerization and ligand binding affect the structure network of A2A adenosine receptor. Biochimica Et Biophysica Acta - Biomembranes, 2011, 1808, 1256-1266.	1.4	59
28	Comparison of the isomerization mechanisms of human melanopsin and invertebrate and vertebrate rhodopsins. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1714-1719.	3.3	59
29	webPSN v2.0: a webserver to infer fingerprints of structural communication in biomacromolecules. Nucleic Acids Research, 2020, 48, W94-W103.	6.5	56
30	Conserved amino acids participate in the structure networks deputed to intramolecular communication in the lutropin receptor. Cellular and Molecular Life Sciences, 2011, 68, 1227-1239.	2.4	54
31	Synthesis, Screening, and Molecular Modeling of New Potent and Selective Antagonists at the α1dAdrenergic Receptor. Journal of Medicinal Chemistry, 2004, 47, 1900-1918.	2.9	52
32	The Formation of a Salt Bridge Between Helices 3 and 6 Is Responsible for the Constitutive Activity and Lack of Hormone Responsiveness of the Naturally Occurring L457R Mutation of the Human Lutropin Receptor. Journal of Biological Chemistry, 2005, 280, 26169-26176.	1.6	52
33	A Mixed Protein Structure Network and Elastic Network Model Approach to Predict the Structural Communication in Biomolecular Systems: The PDZ2 Domain from Tyrosine Phosphatase 1E As a Case Study. Journal of Chemical Theory and Computation, 2013, 9, 2504-2518.	2.3	52
34	A Small Chaperone Improves Folding and Routing of Rhodopsin Mutants Linked to Inherited Blindness. IScience, 2018, 4, 1-19.	1.9	50
35	Gonadotropin-Independent Precocious Puberty Due to Luteinizing Hormone Receptor Mutations in Brazilian Boys: A Novel Constitutively Activating Mutation in the First Transmembrane Helix. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4799-4805.	1.8	50
36	Gonadotropin-Independent Precocious Puberty Due to Luteinizing Hormone Receptor Mutations in Brazilian Boys: A Novel Constitutively Activating Mutation in the First Transmembrane Helix1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4799-4805.	1.8	49

#	Article	IF	CITATIONS
37	WebPSN: a web server for high-throughput investigation of structural communication in biomacromolecules. Bioinformatics, 2015, 31, 779-781.	1.8	49
38	Deciphering the Deformation Modes Associated with Function Retention and Specialization in Members of the Ras Superfamily. Structure, 2010, 18, 402-414.	1.6	46
39	Theoretical study on mutation-induced activation of the luteinizing hormone receptor 1 1Edited by F. E. Cohen. Journal of Molecular Biology, 2000, 296, 1333-1351.	2.0	45
40	Quaternary structure predictions of transmembrane proteins starting from the monomer: a docking-based approach. BMC Bioinformatics, 2006, 7, 340.	1.2	45
41	Network-level analysis of light adaptation in rod cells under normal and altered conditions. Molecular BioSystems, 2009, 5, 1232.	2.9	45
42	Enantiomeric resolution of sulfoxides on a DACH-DNB chiral stationary phase: A quantitative structure-enantioselective retention relationship (QSERR) study. Chirality, 1993, 5, 527-537.	1.3	44
43	Intrinsic Differences in the Response of the Human Lutropin Receptor Versus the Human Follitropin Receptor to Activating Mutations. Journal of Biological Chemistry, 2007, 282, 25527-25539.	1.6	44
44	<i>&gt;a</i> -ARM: Automatic Rhodopsin Modeling with Chromophore Cavity Generation, Ionization State Selection, and External Counterion Placement. Journal of Chemical Theory and Computation, 2019, 15, 3134-3152.	2.3	44
45	Rhodopsin Activation Follows Precoupling with Transducin:  Inferences from Computational Analysis,. Biochemistry, 2005, 44, 14695-14700.	1.2	40
46	The DRY Motif as a Molecular Switch of the Human Oxytocin Receptor. Biochemistry, 2005, 44, 9990-10008.	1.2	39
47	Structural insights into retinitis pigmentosa from unfolding simulations of rhodopsin mutants. FASEB Journal, 2010, 24, 3196-3209.	0.2	39
48	Nucleotide Binding Switches the Information Flow in Ras GTPases. PLoS Computational Biology, 2011, 7, e1001098.	1.5	39
49	Ab InitioModeling and Molecular Dynamics Simulation of the α1b-Adrenergic Receptor Activation. Methods, 1998, 14, 302-317.	1.9	38
50	Pleiotropic Effects of Substitutions of a Highly Conserved Leucine in Transmembrane Helix III of the Human Lutropin/Choriogonadotropin Receptor with Respect to Constitutive Activation and Hormone Responsiveness. Molecular Endocrinology, 2001, 15, 972-984.	3.7	38
51	Mechanisms of Inter- and Intramolecular Communication in GPCRs and G Proteins. Journal of the American Chemical Society, 2008, 130, 4310-4325.	6.6	37
52	Insight into Mutation-Induced Activation of the Luteinizing Hormone Receptor: Molecular Simulations Predict the Functional Behavior of Engineered Mutants at M398. Molecular Endocrinology, 2004, 18, 1499-1508.	3.7	35
53	The catalytic site structural gate of adenosine deaminase allosterically modulates ligand binding to adenosine receptors. FASEB Journal, 2013, 27, 1048-1061.	0.2	35
54	Isoxazolo-[3,4- d ]-pyridazin-7-(6 H )-ones and their Corresponding 4,5-Disubstituted-3-(2 H) Tj ETQq0 0 0 rgB1 Modeling, and Binding Studies. Bioorganic and Medicinal Chemistry, 1998, 6, 925-935.	/Overlock 1 1.4	10 Tf 50 67 To 33

4

#	Article	IF	CITATIONS
55	Dimerization of the lutropin receptor: Insights from computational modeling. Molecular and Cellular Endocrinology, 2007, 260-262, 59-64.	1.6	33
56	The luteinizing hormone receptor: Insights into structure–function relationships and hormone-receptor-mediated changes in gene expression in ovarian cancer cells. Molecular and Cellular Endocrinology, 2010, 329, 47-55.	1.6	32
57	Theoretical study of the electrostatically driven step of receptor-G protein recognition. , 1999, 37, 145-156.		31
58	Homodimerization of Neurotensin 1 Receptor Involves Helices 1, 2, and 4: Insights from Quaternary Structure Predictions and Dimerization Free Energy Estimations. Journal of Chemical Information and Modeling, 2008, 48, 1669-1678.	2.5	31
59	Network and Atomistic Simulations Unveil the Structural Determinants of Mutations Linked to Retinal Diseases. PLoS Computational Biology, 2013, 9, e1003207.	1.5	31
60	Epilepsy and intellectual disability linked protein Shrm4 interaction with GABABRs shapes inhibitory neurotransmission. Nature Communications, 2017, 8, 14536.	5.8	31
61	Molecular basis of ligand binding and receptor activation in the oxytocin and vasopressin receptor family. Experimental Physiology, 2000, 85, 59s-66s.	0.9	30
62	Molecular Dynamics Simulations of the Ligand-Induced Chemical Information Transfer in the 5-HT1AReceptor. Journal of Chemical Information and Computer Sciences, 2003, 43, 1520-1531.	2.8	29
63	An Intracellular Loop (IL2) Residue Confers Different Basal Constitutive Activities to the Human Lutropin Receptor and Human Thyrotropin Receptor through Structural Communication between IL2 and Helix 6, via Helix 3. Endocrinology, 2008, 149, 1705-1717.	1.4	29
64	Membrane Estrogen Receptor (GPER) and Follicle-Stimulating Hormone Receptor (FSHR) Heteromeric Complexes Promote Human Ovarian Follicle Survival. IScience, 2020, 23, 101812.	1.9	29
65	Phenylpiperazinylalkylamino Substituted Pyridazinones as Potent α1Adrenoceptor Antagonists. Journal of Medicinal Chemistry, 2001, 44, 2403-2410.	2.9	28
66	Prediction of MEF2A–DNA interface by rigid body docking: A tool for fast estimation of protein mutational effects on DNA binding. Journal of Structural Biology, 2006, 153, 278-283.	1.3	28
67	Small-Molecule Protein-Protein Interaction Inhibitor of Oncogenic Rho Signaling. Cell Chemical Biology, 2016, 23, 1135-1146.	2.5	28
68	α1-Adrenoceptor subtype selectivity: Molecular modelling and theoretical quantitative structure—affinity relationships. Bioorganic and Medicinal Chemistry, 1997, 5, 809-816.	1.4	27
69	Theoretical quantitative structure-activity relationship analysis of congeneric and non-congeneric α1-adrenoceptor antagonists: a chemometric study. Computational and Theoretical Chemistry, 1995, 331, 79-93.	1.5	26
70	Structure-Function Relationships of the Luteinizing Hormone Receptor. Annals of the New York Academy of Sciences, 2005, 1061, 41-54.	1.8	26
71	Inactive and active states and supramolecular organization of GPCRs: insights from computational modeling. Journal of Computer-Aided Molecular Design, 2006, 20, 449-461.	1.3	26
72	Contributions of Intracellular Loops 2 and 3 of the Lutropin Receptor in Gs Coupling. Molecular Endocrinology, 2008, 22, 126-138.	3.7	26

#	Article	IF	CITATIONS
73	Modulation of thermal noise and spectral sensitivity in Lake Baikal cottoid fish rhodopsins. Scientific Reports, 2016, 6, 38425.	1.6	26
74	Frontiers in Multiscale Modeling of Photoreceptor Proteins. Photochemistry and Photobiology, 2021, 97, 243-269.	1.3	26
75	Computational quantum chemistry and adaptive ligand modeling in mechanistic QSAR. Drug Discovery Today, 2010, 15, 859-866.	3.2	25
76	Catching Functional Modes and Structural Communication in Dbl Family Rho Guanine Nucleotide Exchange Factors. Journal of Chemical Information and Modeling, 2015, 55, 1878-1893.	2.5	24
77	Theoretical quantitative structure—activity relationship analysis on three dimensional models of ligand—m1 muscarinic receptor complexes. Bioorganic and Medicinal Chemistry, 1994, 2, 195-211.	1.4	23
78	Light on the structure of thromboxane A2 receptor heterodimers. Cellular and Molecular Life Sciences, 2011, 68, 3109-3120.	2.4	23
79	Structural features of the inactive and active states of the melanin-concentrating hormone receptors: Insights from molecular simulations. Proteins: Structure, Function and Bioinformatics, 2004, 56, 430-448.	1.5	22
80	ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine. Nature Communications, 2020, 11, 5938.	5.8	22
81	Lutropin Receptor Function: Insights from Natural, Engineered, and Computer-Simulated Mutations. IUBMB Life, 2001, 51, 149-155.	1.5	21
82	Monomeric dark rhodopsin holds the molecular determinants for transducin recognition: Insights from computational analysis. FEBS Letters, 2007, 581, 944-948.	1.3	21
83	Multiscale quantum chemical approaches to QSAR modeling and drug design. Drug Discovery Today, 2014, 19, 1921-1927.	3.2	21
84	Structure network analysis to gain insights into GPCR function. Biochemical Society Transactions, 2016, 44, 613-618.	1.6	21
85	Conformational analysis, molecular modeling and quantitative structure-activity relationship studies of 2,4-diamino-6,7-dimethoxy-2-substituted quinazoline î±1-adrenergic antagonists. Computational and Theoretical Chemistry, 1991, 251, 307-318.	1.5	20
86	Molecular modelling and quantitative structure- activity relationship analysis using theoretical descriptors of 1,4-benzodioxan (WB-4101) related compounds α1-adrenergic antagonists. Computational and Theoretical Chemistry, 1992, 276, 327-340.	1.5	20
87	Molecular dynamics simulations of m3-muscarinic receptor activation and QSAR analysis. Bioorganic and Medicinal Chemistry, 1995, 3, 1465-1477.	1.4	20
88	Computer simulations of signal transduction mechanism in α1B-adrenergic and m3-muscarinic receptors. Protein Engineering, Design and Selection, 1995, 8, 557-564.	1.0	20
89	In Silico Screening of Mutational Effects on Transmembrane Helix Dimerization:  Insights from Rigid-Body Docking and Molecular Dynamics Simulations. Journal of Physical Chemistry B, 2007, 111, 9114-9124.	1.2	20
90	Computational modeling approaches to quantitative structure–binding kinetics relationships in drug discovery. Drug Discovery Today, 2018, 23, 1396-1406.	3.2	20

#	Article	lF	CITATIONS
91	Theoretical study on receptor-G protein recognition: New insights into the mechanism of the ?1b-adrenergic receptor activation. International Journal of Quantum Chemistry, 1999, 73, 71-83.	1.0	19
92	Network Analysis to Uncover the Structural Communication in GPCRs. Methods in Cell Biology, 2013, 117, 43-61.	0.5	19
93	Light on the structural communication in Ras GTPases. Journal of Biomolecular Structure and Dynamics, 2013, 31, 142-157.	2.0	19
94	The heuristic-direct approach to quantitative structure-activity relationship analysis. Computational and Theoretical Chemistry, 1993, 285, 147-153.	1.5	18
95	Comparative molecular dynamics study of the seven-helix bundle arrangement of G-protein coupled receptors. Computational and Theoretical Chemistry, 1995, 333, 49-69.	1.5	18
96	In silico screening of mutational effects on enzyme-proteic inhibitor affinity: a docking-based approach. BMC Structural Biology, 2007, 7, 37.	2.3	17
97	PSNtools for standalone and web-based structure network analyses of conformational ensembles. Computational and Structural Biotechnology Journal, 2022, 20, 640-649.	1.9	17
98	Theoretical quantitative size and shape activity and selectivity analyses of 5-HT1A serotonin and α1-adrenergic receptor ligands. Computational and Theoretical Chemistry, 1994, 305, 101-110.	1.5	16
99	Computational Modeling of Intramolecular and Intermolecular Communication in GPCRs. Current Protein and Peptide Science, 2009, 10, 173-185.	0.7	16
100	Structural Aspects of Luteinizing Hormone Receptor: Information from Molecular Modeling and Mutagenesis. Endocrine, 2002, 18, 285-294.	2.2	15
101	Constitutively Active G Protein-Coupled Receptor Mutants: Implications on Receptor Function and Drug Development Technologies, 2003, 1, 311-316.	0.6	15
102	Probing Fragment Complementation by Rigid-Body Docking:  in Silico Reconstitution of Calbindin D9k. Journal of Chemical Information and Modeling, 2005, 45, 1429-1438.	2.5	15
103	Theoretical quantitative structure-activity analysis and pharmacophore modelling of selective non-congeneric l±1a-adrenergic antagonists. Computational and Theoretical Chemistry, 1993, 280, 283-290.	1.5	14
104	Computer Modeling of Size and Shape Descriptors of α1-Adrenergic Receptor Antagonists and Quantitative Structure–Affinity/Selectivity Relationships. Methods, 1998, 14, 239-254.	1.9	14
105	The α1a and α1b-adrenergic receptor subtypes: molecular mechanisms of receptor activation and of drug action. Pharmaceutica Acta Helvetiae, 2000, 74, 173-179.	1.2	14
106	Superactive mutants of thromboxane prostanoid receptor: functional and computational analysis of an active form alternative to constitutively active mutants. Cellular and Molecular Life Sciences, 2010, 67, 2979-2989.	2.4	14
107	Quaternary Structure Predictions and Structural Communication Features of GPCR Dimers. Progress in Molecular Biology and Translational Science, 2013, 117, 105-142.	0.9	14
108	The heuristic-direct approach to theoretical quantitative structure-activity relationship analysis of $\hat{l}\pm 1$ -adrenoceptor ligands. Computational and Theoretical Chemistry, 1994, 314, 265-276.	1.5	13

#	Article	IF	CITATIONS
109	Structural determinants involved in the activation and regulation of G proteinâ€coupled receptors: lessons from the alpha1â€adrenegic receptor subtypes. Biology of the Cell, 2004, 96, 327-333.	0.7	13
110	Different Structural Requirements for the Constitutive and the Agonist-induced Activities of the β2-Adrenergic Receptor. Journal of Biological Chemistry, 2005, 280, 23464-23474.	1.6	13
111	Sequential Unfolding of Individual Helices of Bacterioopsin Observed in Molecular Dynamics Simulations of Extraction from the Purple Membrane. Biophysical Journal, 2006, 91, 3276-3284.	0.2	13
112	Dark and photoactivated rhodopsin share common binding modes to transducin. FEBS Letters, 2008, 582, 991-996.	1.3	13
113	Dissecting intrinsic and ligand-induced structural communication in the β3 headpiece of integrins. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 2367-2381.	1.1	13
114	Interconnecting Flexibility, Structural Communication, and Function in RhoGEF Oncoproteins. Journal of Chemical Information and Modeling, 2019, 59, 4300-4313.	2.5	13
115	Computational Screening of Rhodopsin Mutations Associated with Retinitis Pigmentosa. Journal of Chemical Theory and Computation, 2009, 5, 2472-2485.	2.3	12
116	Structure–activity relationships in 1,4-benzodioxan-related compounds. 10. Novel α1-adrenoreceptor antagonists related to openphendioxan: Synthesis, biological evaluation, and α1d computational study. Bioorganic and Medicinal Chemistry, 2010, 18, 7065-7077.	1.4	12
117	Nucleotide Binding Affects Intrinsic Dynamics and Structural Communication in Ras GTPases. Current Pharmaceutical Design, 2013, 19, 4214-4225.	0.9	12
118	Theoretical quantitative structure-activity analysis of quinuclidine-based muscarinic cholinergic receptor ligands. Computational and Theoretical Chemistry, 1993, 283, 63-71.	1.5	11
119	Prototropic molecular forms and theoretical descriptors in QSAR analysis. Computational and Theoretical Chemistry, 1995, 333, 1-17.	1.5	11
120	Conformational analysis and theoretical quantitative size and shape-affinity relationships of N4-protonated N1-arylpiperazine 5-HT1A serotoninergic ligands. Computational and Theoretical Chemistry, 1997, 397, 129-145.	1.5	11
121	THE α1b-ADRENERGIC RECEPTOR SUBTYPE: MOLECULAR PROPERTIES AND PHYSIOLOGICAL IMPLICATIONS. Journal of Receptor and Signal Transduction Research, 2002, 22, 1-16.	1.3	11
122	Structural determinants involved in the activation and regulation of G protein-coupled receptors: lessons from the alpha1-adrenegic receptor subtypes. Biology of the Cell, 2004, 96, 327-333.	0.7	11
123	Structural Determinants of Constitutive Activation of Gα Proteins: Transducin as a Paradigm. Journal of Chemical Theory and Computation, 2017, 13, 886-899.	2.3	10
124	Theoretical investigation of IL-6 multiprotein receptor assembly. , 1997, 29, 528-548.		9
125	Molecular mechanisms involved in the activation and regulation of the α1-adrenergic receptor subtypes. Il Farmaco, 1998, 53, 273-277.	0.9	9
126	The Extreme C-Terminal Region of Gαs Differentially Couples to the Luteinizing Hormone and β2-Adrenergic Receptors. Molecular Endocrinology, 2011, 25, 1416-1430.	3.7	9

#	Article	IF	CITATIONS
127	Structural aspects of rod opsin and their implication in genetic diseases. Pflugers Archiv European Journal of Physiology, 2021, 473, 1339-1359.	1.3	9
128	Theoretical study of the electrostatically driven step of receptor-G protein recognition. Proteins: Structure, Function and Bioinformatics, 1999, 37, 145-56.	1.5	9
129	Quaternary structure predictions and estimation of mutational effects on the free energy of dimerization of the OMPLA protein. Journal of Structural Biology, 2008, 163, 155-162.	1.3	8
130	Frontal Variant of Alzheimer's Disease: A Report of a Novel PSEN1 Mutation. Journal of Alzheimer's Disease, 2019, 70, 11-15.	1.2	8
131	Structure-Function Relationships of the α <sub>1b</sub> -Adrenergic Receptor. European Urology, 1999, 36, 11-16.	0.9	7
132	The ad hoc supermolecule approach to receptor ligand design. Computational and Theoretical Chemistry, 2000, 503, 1-16.	1.5	7
133	Ligand-Receptor Communication and Drug Design. Current Protein and Peptide Science, 2009, 10, 186-193.	0.7	7
134	Dynamics and structural communication in the ternary complex of fully phosphorylated V2 vasopressin receptor, vasopressin, and β-arrestin 1. Biochimica Et Biophysica Acta - Biomembranes, 2020, 1862, 183355.	1.4	6
135	Quantitative structure-affinity/selectivity relationship analysis on three-dimensional models of the complexes between the ETA and ETB receptors and C-terminal endothelin hexapeptide antagonists. Computational and Theoretical Chemistry, 1995, 333, 243-248.	1.5	5
136	Integrated structural modeling and super-resolution imaging resolve GPCR oligomers. Progress in Molecular Biology and Translational Science, 2020, 169, 151-179.	0.9	5
137	Modeling the Structural Communication in Supramolecular Complexes Involving GPCRs. Methods in Molecular Biology, 2012, 914, 319-336.	0.4	4
138	Structure network-based landscape of rhodopsin misfolding by mutations and algorithmic prediction of small chaperone action. Computational and Structural Biotechnology Journal, 2021, 19, 6020-6038.	1.9	4
139	Identification of a Constitutively Active Mutant of the Human Oxytocin Receptor. Advances in Experimental Medicine and Biology, 1998, 449, 367-369.	0.8	3
140	Molecular mechanisms underlying the activation and regulation of the α1B-adrenergic receptor. Biochemical Society Transactions, 1996, 24, 959-963.	1.6	2
141	Computational simulations of stem-cell factor/c-Kit receptor interaction. , 1996, 26, 42-54.		2
142	Class A GPCR: Di/Oligomerization of Glycoprotein Hormone Receptors. , 2017, , 207-231.		2
143	Theoretical study on receptor–G protein recognition: New insights into the mechanism of the α1b-adrenergic receptor activation. , 1999, 73, 71.		1
144	Chapter 8. Uncovering GPCR and G Protein Function by Protein Structure Network Analysis. Chemical Biology, 0, , 198-220.	0.1	1

#	Article	IF	CITATIONS
145	ETNK1 Mutations in Atypical Chronic Myeloid Leukemia Induce a Mutator Phenotype That Can be Reverted with Phosphoethanolamine. Blood, 2020, 136, LBA-5-LBA-5.	0.6	1
146	MOLECULAR MECHANISMS UNDERLYING THE ACTIVATION AND REGULATION OF THE $\hat{1}\pm 1$ -ADRENERGIC RECEPTOR. Biochemical Society Transactions, 1996, 24, 517S-517S.	1.6	0
147	Constitutively active α1B-adrenergic receptor mutants: Potential mechanisms underlying receptor activation. Pharmacochemistry Library, 1997, 28, 421-431.	0.1	0
148	The α1a and α1b-adrenergic receptor subtypes: molecular mechanisms of receptor activation and of drug action. Pharmacochemistry Library, 2000, 31, 173-179.	0.1	0
149	Molecular Dynamics Simulations of the Ligand-Induced Chemical Information Transfer in the 5-HT1A Receptor ChemInform, 2003, 34, no.	0.1	0
150	Computational Modeling Approaches to Structure—Function Analysis of G Protein-Coupled Receptors. ChemInform, 2005, 36, no.	0.1	0
151	Understanding the Mutation-Induced Activation of the Lutropin Receptor from Computer Simulation. , 2002, , 29-38.		0